GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (NAS:CPRX) » Definitions » Cyclically Adjusted PB Ratio

Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Cyclically Adjusted PB Ratio : 10.56 (As of Apr. 28, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Catalyst Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-04-28), Catalyst Pharmaceuticals's current share price is $14.89. Catalyst Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $1.41. Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 10.56.

The historical rank and industry rank for Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

CPRX' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 4.79   Med: 9.15   Max: 19.49
Current: 10.53

During the past years, Catalyst Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 19.49. The lowest was 4.79. And the median was 9.15.

CPRX's Cyclically Adjusted PB Ratio is ranked worse than
90.48% of 641 companies
in the Biotechnology industry
Industry Median: 1.72 vs CPRX: 10.53

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Catalyst Pharmaceuticals's adjusted book value per share data for the three months ended in Dec. 2023 was $3.621. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.41 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Catalyst Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Catalyst Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.46 5.55 8.36 17.19 11.89

Catalyst Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.19 14.19 10.65 8.72 11.89

Competitive Comparison of Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Catalyst Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=14.89/1.41
=10.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catalyst Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Catalyst Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=3.621/129.4194*129.4194
=3.621

Current CPI (Dec. 2023) = 129.4194.

Catalyst Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.326 99.695 0.423
201406 0.613 100.560 0.789
201409 0.545 100.428 0.702
201412 0.510 99.070 0.666
201503 0.812 99.621 1.055
201506 0.765 100.684 0.983
201509 0.733 100.392 0.945
201512 0.670 99.792 0.869
201603 0.610 100.470 0.786
201606 0.559 101.688 0.711
201609 0.518 101.861 0.658
201612 0.474 101.863 0.602
201703 0.423 102.862 0.532
201706 0.402 103.349 0.503
201709 0.372 104.136 0.462
201712 0.790 104.011 0.983
201803 0.743 105.290 0.913
201806 0.693 106.317 0.844
201809 0.624 106.507 0.758
201812 0.494 105.998 0.603
201903 0.498 107.251 0.601
201906 0.615 108.070 0.736
201909 0.757 108.329 0.904
201912 0.848 108.420 1.012
202003 0.964 108.902 1.146
202006 1.075 108.767 1.279
202009 1.511 109.815 1.781
202012 1.634 109.897 1.924
202103 1.721 111.754 1.993
202106 1.832 114.631 2.068
202109 1.926 115.734 2.154
202112 2.008 117.630 2.209
202203 2.139 121.301 2.282
202206 2.347 125.017 2.430
202209 2.595 125.227 2.682
202212 2.854 125.222 2.950
202303 3.150 127.348 3.201
202306 3.524 128.729 3.543
202309 3.270 129.860 3.259
202312 3.621 129.419 3.621

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Catalyst Pharmaceuticals  (NAS:CPRX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Catalyst Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Executives
Molly Harper director 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
David S Tierney director C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Alicia Grande officer: Chief Accounting Officer 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Gary Ingenito officer: Chief Medical Officer 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Steve Miller officer: VP Development & Management 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Tamar Thompson director C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Patrick J Mcenany director, 10 percent owner, officer: President and Chief Executive C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Carmen Jeffrey Del officer: Chief Commercial Officer 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Brian Elsbernd officer: Chief Compliance/Legal Officer 355 ALHAMBRA CIRCLE, CORAL GABLES FL 33134
Philip H Coelho director C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Charles B O'keeffe director 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Donald A Denkhaus director 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Preethi Sundaram officer: Chief Product Devel. Officer 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Daniel Brennan officer: Chief Commercial Officer C/O INSYS THERAPEUTICS, INC, 1333 SOUTH SPECTRUM BLVD, SUITE 100, CHANDLER AZ 85286
M Douglas Winship officer: V.P. of Regulatory Operations 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134

Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Headlines